An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis

Windrichova, Jindra; Kučera, Radek; Fuchsova, Radka; Topolčan, Ondřej; Fiala, Ondřej; Svobodová, Jana; Fínek, Jindřich; Slípková, D

doi:10.1177/1533033818807466

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Darlix et al 23 found that the serum NSE levels were independent prognostic factors for brain metastases in breast cancer patients. In addition, Windrichova et al 24 detected that serum levels of NSE were significantly higher in patients with bone metastases compared with metastasis-free patients. In consistence with previous studies, our study indicated that serum NSE was an independent risk factor for bone metastasis in lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer

et al. 2017

View full text Add to dashboard Cite

Lung cancer is a malignant tumor with high metastatic ability and bone is the most common site of distant metastasis of it. However, the independent risk factors for bone metastases of lung cancer remain largely to be elucidated. Here, we conducted a retrospective study to evaluate the correlation between clinical-pathological parameters, serum levels of neuron-specific enolase and CYFRA21-1, and bone metastases in lung cancer patients. The results revealed that patients with bone metastases were younger than those without metastases. Adenocarcinoma was the most frequent type of histopathology in patients with bone metastases. And the incidence of bone metastasis in patients with adenocarcinoma was significantly higher than those with other histopathological subtypes ( p < 0.001). Furthermore, the serum concentration of neuron-specific enolase was significantly higher in patients with bone lesions than those without bone metastases. Multivariate logistic regression analysis showed that patients' age (odds ratio = 1.024, p < 0.001), concentrations of neuron-specific enolase (odds ratio = 1.212, p = 0.004), and histopathological types (odds ratio = 0.995, p = 0.001) were the independent risk factors for bone metastases in patients with lung cancer. Thus, physicians should pay attention to these factors in order to identify bone metastasis earlier while patient was primarily diagnosed as having lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All samples were collected in the early morning, after an overnight fast. BALP, CTX and OC levels were measured by using a chemiluminescence immunoassay, as described [ 15 , 17 , 24 , 25 ], while NTX and OPG were dosed through an immunoenzymatic assay (ELISA) [ 25 , 26 ]. Assessment of all BTM was performed in a CLIA-certified laboratory.…”

Section: Methodsmentioning

confidence: 99%

“…Several efforts have also been made to evaluate the potential role of bone turnover markers (BTM), which are susceptible to non-invasive measurement in blood and urine [ 10 – 12 ], as a surrogate for radiological imaging [ 12 – 15 ], and/or as prognostic biomarkers in patients with metastatic bone disease [ 16 – 20 ]. However, conflicting results emerged from such studies, with high inter- and intra-individual variability representing a substantial limitation to their routine use [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

D’Oronzo,

Cives,

Lauricella

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Bone metastases (BM) are a serious cancer complication, potentially causing substantial morbidity. Among the clinical issues related to BM, there is the lack of specific tools for early diagnosis and prognosis. We explored whether combining bone turnover markers (BTM) with dual-energy X-ray absorptiometry (DXA) assessment could identify early BM progression and risk of skeletal-related events (SREs) during zoledronate treatment. Before the initiation of zoledronate (T0) and after six months of treatment (T1), serum levels of five BTM were measured, and patients (N = 47) underwent DXA evaluation. Standard radiological imaging was performed to assess bone tumor response to medical anti-cancer treatment. High tumor burden in bone correlated with higher serum CTX (p = 0.007) and NTX (p = 0.005) at baseline. Low concentrations of OPG at T0 predicted BM progression with a sensitivity and specificity of 63% and 77%, respectively, when a cutoff of 5.2 pmol/l was used; such a predictive meaning was stronger in patients with lytic BM (sensitivity: 88%, specificity: 80%; p = 0.0006). As for the risk of SREs, we observed an association between low baseline OC (p = 0.04) and OPG (p = 0.08) and the onset of any-time SREs, whereas an increase in OPG over time was associated with reduced risk of on-study events (p = 0.03). Moreover, a statistically significant correlation emerged between low baseline lumbar T-score and femur BMD and on-study SREs (p < 0.001 in both instances). These findings suggest that addition of DXA to BTM dosage could help stratifying the risk of SREs at the time of BM diagnosis but does not enhance our capability of detecting bone progression, during zoledronate treatment.

show abstract

Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications

Baldessari

Pipitone

Molinaro³

et al. 2023

Cancers

View full text Add to dashboard Cite

Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone metastases start with the tropism of cancer cells to the bone through different multi-step tumor–host interactions, as described by the “metastatic cascade” model. Understanding these mechanisms, although far from being fully elucidated, could offer several potential targets for prevention and therapy. Moreover, the prognosis of patients is markedly influenced by skeletal-related events. They can be correlated not only with bone metastases, but also with “bad” bone health. There is a close correlation between osteoporosis—a skeletal disorder with decreased bone mass and qualitative alterations—and prostate cancer, in particular when treated with androgen deprivation therapy, a milestone in its treatment. Systemic treatments for prostate cancer, especially with the newest options, have improved the survival and quality of life of patients with respect to skeletal-related events; however, all patients should be evaluated for “bone health” and osteoporotic risk, both in the presence and in the absence of bone metastases. Treatment with bone-targeted therapies should be evaluated even in the absence of bone metastases, as described in special guidelines and according to a multidisciplinary evaluation.

show abstract

An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis

Cited by 3 publications

References 23 publications

Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer

Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer

Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications

Contact Info

Product

Resources

About